cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Crispr Therapeutics Ag
267 own
103 watching
Current Price
$60.67
$-2.24
(-3.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,812.49M
52-Week High
52-Week High
91.10000
52-Week Low
52-Week Low
37.55000
Average Volume
Average Volume
1.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
16.7148
iconMarket Capitalization4,812.49M
icon52-Week High91.10000
icon52-Week Low37.55000
iconAverage Volume1.08M
iconDividend Yield--
iconP/E Ratio16.7148
What does the Crispr Therapeutics Ag do?
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Read More
How much money does Crispr Therapeutics Ag make?
News & Events about Crispr Therapeutics Ag.
InvestorPlace
9 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 The post 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025 appeared first on ...
Globe Newswire
10 months ago
ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to ...
Business Wire
10 months ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary...
Benzinga
10 months ago
The FDA has accepted the application forVertex Pharmaceuticals IncorporatedandCRISPR Therapeutics AG(NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent Latest Ratings for CRSP DateFirmActionFromTo Feb 2022RBC CapitalMaintainsSector Perform Feb 2022SVB ...
Accesswire
1 year ago
BRENTWOOD, TN / ACCESSWIRE / April 11, 2023 / The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.A burgeoning sector within biotech is the cell...
Frequently Asked Questions
Frequently Asked Questions
What is Crispr Therapeutics Ag share price today?
plus_minus_icon
Can Indians buy Crispr Therapeutics Ag shares?
plus_minus_icon
How can I buy Crispr Therapeutics Ag shares from India?
plus_minus_icon
Can Fractional shares of Crispr Therapeutics Ag be purchased?
plus_minus_icon
What are the documents required to start investing in Crispr Therapeutics Ag stocks?
plus_minus_icon
What is today’s traded volume of Crispr Therapeutics Ag?
plus_minus_icon
What is today’s market capitalisation of Crispr Therapeutics Ag?
plus_minus_icon
What is the 52-Week High and Low Range of Crispr Therapeutics Ag?
plus_minus_icon
What percentage is Crispr Therapeutics Ag down from its 52-Week High?
plus_minus_icon
What percentage is Crispr Therapeutics Ag up from its 52-Week Low?
plus_minus_icon
Current Price
$60.67
$-2.24
(-3.56%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00